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GVHD increases the risk of invasive fungal infections (IFIs).
This randomized phase II selection design study was per-
formed to compare the efﬁcacy and safety of voriconazole
(VRCZ: n¼33) and itraconazole (ITCZ: n¼33) in patients with
GVHD.
The study was conducted fromMarch 2009 through October
2011. Adult patients who had undergone allogeneic he-
matopoietic stem cell transplantation were eligible to
participate in the study if they had either grade II to IV acute
GVHD or chronic GVHD requiring corticosteroid treatment (
PSL>¼0.3 mg/kg/day). VRCZ was administered in the form of
tablets at a dose of 200 mg twice daily, and ITCZ was
administered as oral solution at a dose of 2.5 mg/kg twice
daily.
The primary composite endpoint, success of prophylaxis, was
deﬁned as survival without proven/probable IFI for 60 days
and ability to receive study drug for at least 48 of the 60 days
of planned administration.
Age, underlying disease, disease risk, donor type, condi-
tioning intensity and proportion of patients with acute or
chronic GVHD were similar between the two groups. The
proportion of patients who required dose escalation of the
steroid was signiﬁcantly higher in the VRCZ group (VRCZ 32%
vs. ITCZ 9%, P¼.03).
The success rate of prophylaxis was comparable between the
two groups (VRCZ 88% vs. ITCZ 94%; Difference -6.1%, 95% CI
-20 to 7.7%). In the ITCZ group, one patient each developed
probable and possible IFI after 42 and 33 days of prophylaxis,respectively. In the VRCZ group, one patient developed
possible IFI after 59 days of prophylaxis. Therewas no fungal-
related mortality. The causes of prophylaxis failure included
death due to AML, cytopenia, atrial ﬂutter, and catheter-
related infection in the VRCZ group (n¼4), and probable IFI
and withdrawal of consent in the ITCZ group (n¼2).
The incidence of SAE (CTCAE v3 grade 3/4) was not different
between the two groups (VRCZ 27% vs. ITCZ 21%, P¼.77). The
most frequent event was liver dysfunction in both groups
(VRCZ 18% vs. ITCZ 12%, P¼.73), but gastrointestinal events
were seen only in the ITCZ group (VRCZ 0% vs. ITCZ 6%,
P¼.49). A total of 4 patients, exclusively in the ITCZ group,
required intravenous administration of the study drug for
longer than 14 days (20-23 days), and 3 of the 4 patients had
gut acute GVHD. A total of 4 patients received other systemic
anti-mold agents during the study period (VRCZ 9% vs. ITCZ
3%, P¼.61). However, none received these agents for longer
than 14 days (7-10 days) and only one of these patients in the
ITCZ group developed possible IFI.
Both the overall survival rate and the cumulative incidence
rate of non-relapse mortality were similar at 3 years after
randomization between the VRCZ and ITCZ groups (67% vs.
49%, P¼.20 by the log-rank test and 14% vs. 26%, P¼.31 by the
Gray test, respectively).
In conclusion, our study suggested that both VRCZ and ITCZ
were feasible for and effective as an antifungal prophylaxis in
patients with GVHD.103
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Alternative donors (umbilical cord blood (UCB), hap-
loidentical family members, or mismatched unrelated do-
nors (MMUD) allow patients without matched sibling or
unrelated (MUD) donors to proceed to a potentially curative
HCT. Retrospective studies have shown comparable out-
comes among different alternative graft sources, but differ-
ences in infection rates have not been well studied. We
compared incidences of bacterial, viral, and fungal infections
at 1 year post HCT in patients reported to the CIBMTR who
were 16 years with acute leukemia in remission who
received an alternative donor HCT between 2008 and 2011.
Patients were included if they had received HCT in 1st/ 2nd CR
using UCB, 8/8 allele matched MUD or 7/8 antigen/allele
MMUD. Recipients of 467 UCB, 869 MUD and 268 MMUD
grafts were included. UCB recipients were younger and had
better performance status; they were more likely to have
acute lymphoblastic leukemia, not receive antithymocyte
globulin, and be transplanted in CR 2 with reduced intensity
conditioning regimens. The incidence at 1 year of bacterial,
fungal and viral infections in each cohort are shown in Table
1. There were no differences by pairwise comparisons
Table 1
Cumulative incidence of infection at 1 year with 95% CI
UCB MUD MMUD p-value
Bacterial 71% (66-75%) 63% (59-66%) 66% (60-71%) .01
Fungal 15% (12-18%) 8% (7-11%) 13% (9-17%) .002
Virus (all) 69% (65-73%) 44% (41-47%) 54% (48-60%) P<.0001
Table 2
Rate of viral infections per patient per year, stratiﬁed by graft source
Virus UCB MUD MMUD p-value
CMV 0.783 0.411 0.598 <.001
Adenovirus 0.099 0.034 0.056 .008
EBV 0.096 0.091 0.152 .04
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fungal infections (p ¼ .52); however, UCB recipients had
signiﬁcantly more viral infections compared to MMUD (p
<.0001).The rate (infections per patient per year) of CMV
reactivation/disease and adenoviral infections was higher in
UCB recipients; MMUD had a higher rate of EBV reactivation
(Table 2). Infection as a cause of death was similar among the
three graft sources at 1 year (41%, 31%, and 38% for UCB,
MUD, andMMUD respectively). Overall survival at 1 year was
50% (46 e 55%), 69% (65 e 72%), and 58% (52 e 64%) for UCB,
MUD, and MMUD respectively (p<.0001) and this difference
was driven by higher treatment related mortality (TRM) as
relapse was similar across the groups. The survival was
slightly higher with MMUD compared to UCB (p<.04). In
conclusion, 1) The incidences of bacterial, fungal, and
particularly viral infections are high after alternative donor
transplant; 2) Infections are a major cause of death in the
ﬁrst year after alternative donor transplant; 3) The incidence
of infection as cause of death was similar among the graft
sources; 4) Viral infections are higher in recipients of UCB
compared to MMUD. Future directions will focus on pre-
ventative techniques and predictors for infection, particu-
larly for viral infections.Table
Results of univariate analyses
Graft type N 100 d
survival, %
(95% CI)
Median total
LOS in ﬁrst
100 d
Median days
alive out of
hospital in
ﬁrst 100 d
Ped MA HCT
Single UCB 219 88 (83-92) 47* 50*
Double UCB 80 85 (76-92) 44 55
8/8 URD BM 69 94 (88-98) 40 60
Adult MA HCT
Single UCB 65 74 (63-84)* 40* 52*
Double UCB 146 79 (72-85) 40 55
7/8 URD BM 42 76 (62-88) 32 64
7/8 URD PBSC 126 79 (72-86) 29 67
8/8 URD BM 92 91 (85-96) 29 69
8/8 URD PBSC 297 90 (86-93) 25 75
Adult RIC HCT
Single UCB 16 75 (74-85)* 31* 65*
Double UCB 188 80 (74-85) 33 64
7/8 URD PBSC 77 87 (79-94) 20 79
8/8 URD PBSC 160 93 (89-97) 21 79
*P<.05 for group comparison104
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Use of alternative donors (unrelated umbilical cord blood
(UCB), haploidentical family members, mismatched unre-
lated donors (URD)) allows patients without HLA matched
sibling or unrelated donors to proceed to HCT. Several
retrospective studies show comparable survival outcomes
among different alternative graft sources, but the relative
cost of HCT by graft source has not been well studied. We
compared total hospital length of stay, which included
initial hospitalization and readmissions (LOS) in the ﬁrst
100 days as a surrogate for short-term costs and resource
utilization, in a cohort of alternative donor HCT recipients
reported to the CIBMTR from 2008-2011. Patients were
included if they had received HCT in the US for acute
leukemia in 1st or 2nd CR using UCB or HLA-mismatched
URD. We also included HLA-matched URD HCT recipients
for comparison; there were too few haploidentical HCT
reported to the CIBMTR during this time period to allow
comparisons. The cohort was restricted to patients
receiving similar conditioning and GVHD prophylaxis reg-
imens. We analyzed the 1577 eligible patients in three
separate groups: pediatric HCT after myeloablative (MA)
conditioning (age 18 y, N¼368), adult HCT after MA
conditioning (N¼768) and adult HCT after reduced in-
tensity conditioning (RIC, N¼441).Within each of these
three groups, we compared match/donor categories with
sufﬁcient number of patients. There was no difference in
HCT comorbidity index scores by graft sources in any
group. Table 1 shows 100 day overall survival and the
median total LOS in the ﬁrst 100 days after HCT. To account
for the differential rates of 100 day mortality in some co-
horts, we also describe median days alive out of hospital in
ﬁrst 100 days. In univariate analyses, single and double
UCB HCT recipients had longer LOS than patients receiving
other graft sources, but there was no difference in LOS
between single and double UCB recipients. In conclusion;
LOS in the ﬁrst 100 days varies substantially by graft
source, with LOS being greater for UCB HCT recipients. LOS
is similar between single and double UCB. Ongoing
multivariate analyses will consider LOS among graft sour-
ces while adjusting for patient and disease related vari-
ables. Our data have implications for resource allocation
for alternative donor HCT.
